Ruth Arnon | Academic Influence

Ruth Arnon's AcademicInfluence.com Rankings

Ruth Arnon

Biology

#446

World Rank

#797

Historical Rank

Biochemistry

#207

World Rank

#261

Historical Rank

biology Degrees

Download Badge

Biology

Ruth Arnon's Degrees

PhD Biochemistry Weizmann Institute of Science

Why Is Ruth Arnon Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Ruth Arnon is an Israeli biochemist and codeveloper of the multiple sclerosis drug Copaxone. She is currently the Paul Ehrlich Professor of Immunology at the Weizmann Institute of Science, where she is researching anti-cancer and influenza vaccinations.

(See a Problem?)

Ruth Arnon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide (1971) (421)
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. (1997) (279)
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. (1975) (266)
Monoclonal and polyclonal antibodies against acetaldehyde-containing epitopes in acetaldehyde-protein adducts. (1986) (257)
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. (1994) (233)
Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ (2003) (229)
Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. (2000) (219)
Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine. (1962) (209)
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. (2005) (203)
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. (1999) (187)
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 (1998) (182)
Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications (2004) (178)
A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (1991) (164)
A DNA Aptamer Prevents Influenza Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin* (2004) (161)
Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses (1996) (160)
Neurogenesis and Neuroprotection Induced by Peripheral Immunomodulatory Treatment of Experimental Autoimmune Encephalomyelitis (2005) (145)
Anti-influenza response achieved by immunization with a synthetic conjugate. (1982) (145)
Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. (1971) (141)
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone® (2001) (126)
Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. (1974) (124)
Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. (1978) (119)
Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen (1973) (118)
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. (1988) (117)
Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. (1979) (115)
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. (1992) (113)
The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. (1975) (113)
Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis (2008) (110)
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. (1999) (108)
Studies on the chemical basis of the antigenicity of proteins. 1. Antigenicity of polypeptidyl gelatins. (1960) (108)
Anti-ganglioside antibodies in multiple sclerosis (1980) (108)
Structural basis of antigenic specificity and design of new vaccines (1992) (107)
Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate. (1969) (103)
Successful immunization with a totally synthetic diphtheria vaccine. (1982) (101)
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models (1993) (100)
A universal epitope-based influenza vaccine and its efficacy against H5N1. (2009) (98)
In vivo and in vitro immunological cross‐reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis (1973) (98)
Basic encephalitogenic protein: A simplified purification on sulphoethyl‐sephadex (1970) (95)
Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy (2003) (94)
Chemical characterization and subunit structure of human N-acetylhexosaminidases A and B. (1976) (93)
Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice (1980) (93)
Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. (1976) (91)
Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. (1992) (91)
The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. (1996) (91)
Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. (1996) (90)
Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis Preliminary report (1977) (89)
T suppressor hybridomas and interleukin‐2‐dependent lines induced by copolymer 1 or by spinal cord homogenate down‐regulate experimental allergic encephalomyelitis (1993) (88)
Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs (1988) (88)
Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen–Ia complex (1991) (88)
Multiple sclerosis: Trial of a synthetic polypeptide (1982) (88)
Epitope-based vaccine against influenza (2007) (87)
Chemical and immunological characterization of a unique antigenic region in lysozyme. (1971) (86)
Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. (1990) (85)
Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. (1991) (82)
Experimental Allergic Encephalomyelitis ‐ Susceptibility and Suppression (1981) (82)
In Vitro and In Vivo Efficacy of Conjugates of Daunomycin with Anti‐Tumor Antibodies (1982) (81)
Design of peptide and polypeptide vaccines. (1997) (81)
Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing–remitting or chronic EAE (2010) (79)
Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59 (1994) (79)
Antibodies to papain. A selective fractionation according to inhibitory capacity. (1967) (79)
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease (1996) (78)
Copolymer 1: from basic research to clinical application (1997) (77)
Chromatin conformation governs T-cell receptor Jβ gene segment usage (2012) (77)
Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of hemagglutinin. (1984) (75)
Old and new vaccine approaches. (2003) (75)
Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. (2011) (74)
Cellular immune response to peripheral nerve basic protein in idiopathic facial paralysis (Bell's palsy) (1975) (73)
Antibodies against synthetic peptides of the B subunit of cholera toxin: crossreaction and neutralization of the toxin. (1983) (72)
Immunomodulation by the copolymer glatiramer acetate (2003) (70)
Cell‐mediated immunity to neural antigens in idiopathic polyneuritis and myeloradiculitis (1975) (70)
Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. (1998) (68)
Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. (2014) (67)
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis (2012) (67)
Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. (2002) (67)
The effect in vivo of chemotherapeutic drug—antibody conjugates in two murine experimental tumor systems (1978) (66)
Studies on the chemical basis of the antigenicity of proteins. 2. Antigenic specificity of polytyrosyl gelatins. (1960) (63)
Cleavage of one specific disulfide bond in papain. (1969) (63)
Proteases secreted by transforming schistosomula of Schistosoma mansoni promote resistance to killing by complement. (1988) (62)
Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. (1999) (62)
An immunological approach to the structural relationship between hen egg-white lysozyme and bovine -lactalbumin. (1971) (62)
The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs (1979) (62)
Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. (1995) (61)
Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. (1976) (61)
Schistosoma mansoni: isolation and characterization of Smpi56, a novel serine protease inhibitor. (1994) (61)
Synthetic peptides as vaccines (1992) (60)
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. (1980) (60)
Synthetic peptides as the basis for vaccine design. (1991) (58)
Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate (2009) (57)
The 14‐3‐3 protein as a vaccine candidate against schistosomiasis (2001) (56)
Soluble polymers as carriers of cis-platinum (1989) (55)
Immunochemistry of Enzymes (1973) (54)
Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity (1988) (53)
POLYLYSINE-SPECIFIC ANTIBODIES AND THEIR REACTION WITH OLIGOLYSINES. (1965) (53)
Immunomodulatory Therapeutic Effect of Glatiramer Acetate on Several Murine Models of Inflammatory Bowel Disease (2006) (53)
Immunochemical analysis of the conformational properties of intermediates trapped in the folding and unfolding of bovine pancreatic trypsin inhibitor. (1978) (52)
Enzyme replacement in Tay‐Sachs disease (1979) (52)
Perforin-Positive Dendritic Cells Exhibit an Immuno-regulatory Role in Metabolic Syndrome and Autoimmunity. (2015) (51)
Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system (2002) (51)
Protective monoclonal antibody against Schistosoma mansoni: antigen isolation, characterization, and suitability for active immunization. (1985) (51)
Towards an Epitope-Based Human Vaccine for Influenza (2005) (49)
Immunoreactivities of polyclonal and monoclonal anti‐T and anti‐Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model (1997) (49)
Chemically defined antiviral vaccines. (1980) (49)
Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes of polycarboxylates — effect on human ovarian carcinoma (1998) (48)
Reduced toxicity of daunorubicin by conjugation to dextran. (1982) (48)
Studies on the chemical basis of the antigenicity of proteins. 3. The role of rigidity in the antigenicity of polypeptidyl gelatins. (1960) (48)
A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. (1996) (48)
Intranasal Administration of Synthetic Recombinant Peptide-Based Vaccine Protects Mice from Infection by Schistosoma mansoni (1999) (47)
Acetylcholinesterase in Schistosoma mansoni is anchored to the membrane via covalently attached phosphatidylinositol. (1988) (47)
Complement regulation on the surface of cultured schistosomula and adult worms of Schistosoma mansoni (1990) (46)
Effect of carrier on the immunogenic capacity of synthetic cholera vaccine. (1985) (46)
Efficacy of anti-influenza peptide vaccine in aged mice (1998) (44)
Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate (2013) (44)
Neutralization of heat‐labile toxin of E. coli by antibodies to synthetic peptides derived from the B subunit of cholera toxin. (1984) (44)
Isolation and characterization of active fragments obtained by cleavage of immunoglobulin G with cyanogen bromide. (1966) (43)
Purification and characterization of proteases secreted by transforming schistosomula of Schistosoma mansoni. (1988) (43)
Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. (1997) (43)
Experimental allergic neuritis induced by a basic neuritogenic protein (P1 L) of human peripheral nerve origin (1977) (42)
Schistosoma mansoni: evidence for a 28-kDa membrane-anchored protease on schistosomula. (1996) (41)
Isolation and partial characterization of the tegumental outer membrane of schistosomula of Schistosoma mansoni. (1984) (41)
Schistosoma mansoni: killing of transformed schistosomula by the alternative pathway of human complement. (1986) (41)
Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. (1992) (41)
Antibodies to enzymes--a tool in the study of antigenic specificity determinants. (1971) (41)
NEURITOGENIC AND ENCEPHALITOGENIC PROPERTIES OF THE PERIPHERAL NERVE BASIC PROTEINS (1975) (41)
Priming immunization against cholera toxin and E. coli heat‐labile toxin by a cholera toxin short peptide‐beta‐galactosidase hybrid synthesized in E. coli. (1985) (40)
Daunomycin--immunoglobulin conjugates, uptake and activity in vitro. (1978) (40)
Synthesis of poly‐L‐lysine and poly‐L‐lysyl albumin via ϵ,N‐trifluoroacetyl‐α,N‐carboxy‐L‐lysine anhydride (1963) (39)
Protection against Experimental Allergic Encephalomyelitis (1972) (38)
A mimotope peptide‐based vaccine against Schistosoma mansoni: synthesis and characterization (2000) (38)
Neurogenesis and Neuroprotection in the CNS — Fundamental Elements in the Effect of Glatiramer Acetate on Treatment of Autoimmune Neurological Disorders (2007) (38)
Polymers in drug delivery: immunotargeting of carrier-supported cis-platinum complexes (1995) (37)
The effect of a single amino acid substitution on the antigenic specificity of the loop region of lysozyme. (1980) (37)
A synthetic vaccine against influenza with built-in adjuvanticity. (1985) (37)
The Amino Acid Composition of Chromatographically Purified Pepsinogen (1963) (37)
Conformational changes and complement activation induced upon antigen binding to antibodies. (1977) (36)
New insights into the mechanism of action of copolymer 1 of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis (1996) (36)
Renal accumulation of streptavidin: potential use for targeted therapy to the kidney. (1995) (36)
Oral Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis: Clinical and Immunological Studies (2004) (35)
Schistosoma mansoni: localization of the 28 kDa secreted protease in cercaria (1990) (35)
[Strain-dependent differences in the specificity of antibody responses toward lysozyme]. (1971) (35)
Purification, biochemical and immunological characterisation of hexosaminidase A from variant AB of infantile GM2 gangliosidosis. (1978) (35)
Biochemical and immunochemical characterization of hexosaminidase P. (1978) (35)
Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. (1997) (34)
Copolymer 1 inhibits manifestations of graft rejection. (2001) (34)
Synthetic peptides as the basis for future vaccines (1986) (34)
A selective fractionation of anti-lysozyme antibodies of different determinant specificities. (1968) (33)
Cis-platinum(II) complexes of carboxymethyl-dextran as potential antitumor agents. I. Preparation and characterization. (1986) (33)
A specific synthetic polypeptide antigen. (1960) (33)
The amount of acetylcholinesterase on the parasite surface reflects the differential sensitivity of schistosome species to metrifonate (1994) (33)
Astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosis (2018) (33)
Synthetic Copolymer I and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells (1995) (32)
Structural Transition in Myelin Membrane as Initiator of Multiple Sclerosis. (2016) (32)
Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents. II. In vitro and in vivo activity. (1986) (32)
Phosphatidylinositol-specific phospholipase C induces biosynthesis of acetylcholinesterase via diacylglycerol in Schistosoma mansoni. (1991) (32)
The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. (2007) (32)
Stabilization of human beta-D-N-acetylhexosaminidase A towards proteolytic inactivation by coupling it to poly(N-vinylpyrrolidone). (1977) (31)
The role of specific amino acid residues in the antigenic reactivity of the loop peptide of lysozyme. (1973) (31)
Both cholera toxin-induced adenylate cyclase activation and cholera toxin biological activity are inhibited by antibodies against related synthetic peptides. (1984) (31)
Indirect immunotargeting of CIS‐PT to human epidermoid carcinoma KB using the avidin‐biotin system (1991) (31)
Fab dimers of antitumor immunoglobulins as covalent carriers of daunomycin. (1976) (31)
Therapeutic Effect of the Immunomodulator Glatiramer Acetate on Trinitrobenzene Sulfonic Acid‐Induced Experimental Colitis (2005) (31)
Protection against Schistosoma mansoni achieved by immunization with sonicated parasite (1982) (30)
Purification of human hexosaminidases A and B affinity chromatography (1974) (30)
Immunochemical and biochemical investigation of hexosaminidase S. (1977) (30)
Antibody carriers of drugs and toxins in tumor therapy. (1982) (30)
Expression and immunolocalization of the 14-3-3 protein of Schistosoma mansoni (2001) (30)
CHANGES IN THE GABA SYSTEM IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS‐INDUCED PARALYSIS (1976) (29)
Microculture virus titration--a simple colourimetric assay for influenza virus titration. (1995) (29)
Tissue selective affinity targeting using the avidin–biotin system (2000) (29)
Immunological studies on specific antibodies against trypsin (1966) (29)
Specific excitation energy transfer from antibodies to dansyl-labeled antigen. Studies with the "loop" peptide of hen egg-white lysozyme. (1971) (29)
Acetylcholinesterase of Schistosoma mansoni: antigenic cross‐reactivity with Electrophorus electricus and its functional implications (1984) (28)
Regulation of autosensitisation to encephalitogenic myelin basic protein by macrophage-associated and soluble antigen (1977) (28)
Crystalline papain derivative containing in intramolecular mercury bridge. (1969) (28)
Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. (1990) (27)
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate (2014) (27)
Cell‐mediated vs humoral response in the cross‐reaction between hen egg‐white lysozyme and bovine α‐lactalbumin (1972) (27)
Acetylcholinesterase of schistosoma mansoni—Functional correlates: Contributed in honor of Professor Hans Neurath's 90th birthday (1999) (27)
Labeling of Sperm Cells via the Spontaneous Penetration of Eu3+ Ions as Nanoparticles Complexed with PVA or PVP (2008) (27)
The covalent linking of two nucleotide analogues to antibodies. (1985) (26)
A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. (2002) (26)
Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. (1991) (26)
Increased therapeutic efficacy of CIS‐platinum complexes of poly‐L‐glutamic acid against a murine carcinoma (1987) (25)
Molecular basis of the antigenic difference between two closely related lysozymes of known sequence: effect of internal substitutions. (1974) (25)
Comparison between the antigenic structure of mutually related enzymes. A study with papain and chymopapain. (1968) (25)
Sphingomyelin specific antibodies elicited by synthetic conjugates. (1973) (25)
Immunological comparison of bird and human lysozymes and of their "loop" regions. (1970) (25)
The mechanism of inhibition of papain by its specific antibodies. (1967) (25)
New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. (1996) (24)
Life span of parasite in schistosomiasis patients. (1990) (24)
Lymphocytes sensitised to basic encephalitogen in patients with multiple sclerosis unresponsive to steroid therapy. (1974) (24)
Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome. (2011) (23)
Sequential appearance of antibodies directed against different antigenic determinants of hen egg‐white lysozyme (1971) (23)
Lack of immunological cross-reaction between bovine α-lactalbumin and hen's egg-white lysozyme (1970) (23)
Copolymer 1 from the laboratory to FDA. (1997) (23)
Acetylcholinesterase from Schistosoma mansoni: immunological characterization. (1991) (23)
Suppression of experimental allergic encephalomyelitis by COP1--relevance to multiple sclerosis. (1989) (22)
Astrocyte morphology is confined by cortical functional boundaries in mammals ranging from mice to human (2016) (22)
Antibody-mediated thermal stabilization of human hexosaminidases. (1975) (22)
Relation of Immunological and Enzymic Properties to Structural Modifications of Pepsinogen (1963) (22)
Binding of random copolymers of three amino acids to class II MHC molecules. (1999) (22)
Immunization with influenza virus hemagglutinin globular region containing the receptor-binding pocket. (2002) (22)
Stage-specific expression of the mRNA encoding a 14-3-3 protein during the life cycle of Schistosoma mansoni. (1995) (22)
Modulation of the immune response in multiple sclerosis: production of monoclonal antibodies specific to HLA/myelin basic protein. (1997) (22)
Binding of anti‐tumor immunoglobulins and their daunomycin conjugates to the tumor and its metastases. In vitro and in vivo studies with lewis lung carcinoma (1979) (22)
Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate (2019) (22)
Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines (1994) (22)
A CONJUGATE OF ADRIAMYCIN AND MONOCLONAL ANTIBODIES TO THY‐1 ANTIGEN INHIBITS HUMAN NEUROBLASTOMA CELLS IN VITRO a (1983) (21)
Specificity and cross-reactivity of synthetic peptides derived from a major antigenic site of influenza hemagglutinin. (1985) (21)
Tumor-associated antigens and their specific immune response (1979) (21)
Specific determination of N-acetyl-beta-D-hexosaminidase isozymes A and B by radioimmunoassay and radial immunodiffusion. (1975) (21)
Upper gastrointestinal endoscopy in the pediatric patient. (1994) (21)
Acetylcholinesterase of Schistosoma mansoni. Molecular forms of the solubilized enzyme. (1984) (21)
Glatiramer acetate (Copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. (2003) (20)
Genetic control of immune response toward the loop region of lysozyme. (1973) (20)
Therapeutic vaccines: realities of today and hopes for the future. (2002) (20)
Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. (2005) (19)
Letters to the editor: Correlation of conformation and biological activity in lysozyme "loop" homologs. (1974) (19)
Anti-nuclear antibodies associated with schistosomiasis and anti-schistosomal antibodies associated with SLE. (1994) (19)
Correlation of structural differences in several bird lysozymes and their loop regions with immunological cross-reactivity. (1974) (19)
The immunologic response in mice unresponsive to experimental allergic encephalomyelitis. (1981) (19)
Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative (1985) (19)
A functional peptide encoded in the Escherichia coli 23S rRNA (1996) (19)
Immunological cross-reactivity of antibodies to a synthetic undecapeptide analogous to the amino terminal segment of carcinoembryonic antigen, with the intact protein and with human sera. (1976) (19)
Dynamics of antibody‐ and lectin‐mediated endocytosis of hapten‐containing liposomes by murine macrophages (1981) (18)
Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. (1995) (18)
Cellular studies of the genetic control of immune response toward the loop region of lysozyme. (1973) (18)
The reactoin of papain with antipapain (1965) (18)
An immunological approach to the study of evolution of trypsins. (1969) (18)
Immunity to heat-labile enterotoxins of porcine and human Escherichia coli strains achieved with synthetic cholera toxin peptides (1986) (18)
Anti‐schistosome monoclonal antibodies of different isotypes–correlation with cytotoxicity. (1983) (17)
On the existence of suppressor cells. (1993) (17)
LOVASTATIN AND ELEVATED CREATINE KINASE: RESULTS OF RECHALLENGE (1989) (16)
Carboxy-terminal peptides from the B subunit of Shiga toxin induce a local and parenteral protective effect. (1990) (16)
Preparation of antisera to α‐fetoprotein making use of estradiol affinity column (1973) (16)
Strain differences in susceptibility to experimental allergic encephalomyelitis and the immune response to the encephalitogenic determinant in inbred guinea pigs. (1977) (16)
Site‐directed chemotherapy with a drug bound to anti‐idiotypic antibody to a lymphoma cell‐surface IgM (1983) (16)
Fractionation of functional lymphocytes sensitized to basic encephalitogen on derivatized collagen and gelatin gels. (1975) (16)
Adjuvant effect of a peptidoglycan attached covalently to a synthetic antigen provoking anti-phage antibodies. (1978) (16)
Determination of cystine and other amino acids in the fingernails of members of various ethnic groups in Israel. (1966) (15)
Anti-cholera response elicited by a completely synthetic antigen with built-in adjuvanticity administered in aqueous solution. (1986) (15)
Linkage between immunomodulation, neuroprotection and neurogenesis. (2009) (15)
Inactivation of neurogenic 5-hydroxytryptamine receptors in guinea pigs with experimental allergic encephalomyelitis (EAE) induced paralysis (1977) (15)
Acetylcholinesterase of Schistosoma mansoni: Purification and characterization (1986) (15)
BIOLOGICAL ACTIVITY OF THE CLEAVAGE PRODUCT OF HUMAN IMMUNOGLOBULIN G WITH CYANOGEN BROMIDE (1967) (15)
Isolation of Antibodies to Gelatin from Antigen-Antibody Complex by Proteolysis (1960) (15)
Priming immune response to cholera toxin induced by synthetic peptides (1986) (15)
Age dependent course of EAE in Aire−/− mice (2013) (15)
Cop 1 as a candidate drug for multiple sclerosis. (1997) (15)
Synthetic approaches to vaccines for infectious and autoimmune diseases. (1992) (15)
Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes. (1997) (14)
Genetic control of susceptibility to experimental allergic encephalomyelitis in mice (1979) (14)
Immuno-parasitological parameters in schistosomiasis--a perspective view of a vaccine-oriented immunochemist. (1991) (14)
Effect of phosphonium salts and phosphoranes on the acetylcholinesterase activity and on the viability of Schistosoma mansoni parasites. (1984) (14)
Differential reactivities of the Arachis hypogaea (peanut) and Vicia villosa B4 lectins with human ovarian carcinoma cells, grown either in vitro or in vivo xenograft model (1996) (14)
Quantitative Power Measurement of Extensor Hallucis Longus: A Simple Objective Test in Evaluation of Low‐Back Pain with Neurological Involvement (1983) (13)
Unresponsiveness to experimental allergic encephalomyelitis in mice: replacement of suppressor cells by a soluble factor. (1981) (13)
[59] Hexosaminidases A and B from human placenta (1978) (13)
Astrocytes in Multiple Sclerosis—Essential Constituents with Diverse Multifaceted Functions (2021) (13)
Homology and Phylogeny of Proteolytic Enzymes (1970) (13)
Correlation between strain differences in susceptibility to experimental allergic encephalomyelitis and the immune response to encephalitogenic protein in inbred guinea pigs. (1973) (13)
Synthetic vaccines--a dream or reality. (1972) (13)
GENETIC ANALYSIS OF SUSCEPTIBILITY TO EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN GUINEA‐PIGS (1981) (12)
Lovastatin-induced hepatitis. (1992) (12)
Immunoglobulins in the airway washings and bile secretions of chickens (1974) (12)
Poly-L-cyclohexylalanine and Poly-L-cyclohexylalanyl Proteins (1960) (12)
A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells. (1998) (11)
Immunochemical studies on bovine trypsin and trypsinogen derivatives. (1970) (11)
Clinical Trials of Copolymer I in Multiple Sclerosis (1984) (11)
Clinical experience with COP‐1 in multiple sclerosis (1988) (11)
Peptides as immunogens: prospects for synthetic vaccines. (1986) (11)
Effect of immunization course on inhibitory capacity of anti-enzyme antibodies (1968) (11)
Cellular immune response toward MS-2 phage and a synthetic fragment of its coat protein. (1978) (11)
Fatal outcome of neonatal echovirus 19 infection. (1991) (11)
Specific immunoassay for quantitative determination of human trypsin in intestinal content. (1971) (10)
Peptide-based synthetic recombinant vaccines with anti-viral efficacy. (2001) (10)
Blood levels and serum protein binding of cis-Platinum(II) complexed to carboxymethyl-dextran (2004) (10)
Synthesis and Characterization of a Protective Peptide-Based Vaccine against Schistosoma mansoni (1998) (10)
Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis (2016) (10)
Organ selective delivery using a tissue-directed streptavidin--biotin system: targeting 5-fluorouridine via TNP-streptavidin. (1999) (10)
Liver accumulation of TNP-modified streptavidin and avidin: potential use for targeted radio- and chemotherapy. (1996) (10)
Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in Experimental Autoimmune Encephalomyelitis (2009) (10)
Development of Copolymer 1 (Copaxone®) as a Specific Drug Against Multiple Sclerosis (1999) (10)
Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoni. (1998) (9)
ANTIBODIES TO PEPSINOGEN AND PEPSINOGEN MODIFICATIONS * (1963) (9)
Glatiramer Acetate: from Bench to Bed and Back. (2019) (9)
Acetylcholinesterase of Schistosoma mansoni--an antigen of functional implications. (1987) (9)
Synthetic vaccines: present and future. (1985) (9)
Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: characterization of the specificity. (1983) (9)
ACTIVE FRAGMENTS OBTAINED BY CLEAVAGE OF RABBIT ANTIBODY WITH CYANOGEN BROMIDE. (1965) (9)
Genetic control of immune response to a purified Schistosoma mansoni antigen. I. Effect of MHC class II antigens on the cellular, humoral and protective responses (1989) (9)
Beneficial Effect of Glatiramer Acetate Treatment on Syndecan-1 Expression in Dextran Sodium Sulfate Colitis (2011) (9)
Expression of Shiga toxin epitopes in E. coli immunological characterization. (1989) (9)
Synthetic vaccines. (1938) (8)
Manipulation of autoimmune diseases with T-suppressor cells: lessons from experimental SLE and EAE. (1993) (8)
Enzyme inhibition by antibodies. (1975) (8)
Monoclonal antibodies against acetylcholinesterase of Schistosoma mansoni: production and characterization. (1995) (8)
Structural and functional comparison of antibodies to common and specific determinants of papain and chymopapain. (1973) (8)
Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis (2020) (8)
Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer (2012) (8)
Antibodies as carriers for oncostatic materials. (1980) (8)
Peptide Binding to Class I Molecules of the Major Histocompatibility Complex on the Surface of Living Target Cells (1992) (8)
Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection. (1996) (8)
Idiotype anti-idiotype complexes in cerebrospinal fluids of multiple sclerosis patients (1979) (8)
Genetic control of immune response to a purified Schistosoma mansoni antigen. II. Establishment and characterization of specific I–A and I–E restricted T–cell clones (1989) (7)
Quinidine-induced uveitis. (1992) (7)
In vivo protection against S. mansoni infection by monoclonal antibodies. (1985) (7)
Role of cellular and humoral immunity and helper cell involvement in permissiveness to infection by Schistosoma mansoni (1987) (7)
Treatment of multiple sclerosis with a synthetic polypeptide: preliminary results. (1980) (6)
The immune response of inbred strains of guinea-pigs to polylysyl rabbit serum albumin (1966) (6)
Inverse relationship between net electric charge on the antigen and that on the sensitized cell in cellular immune response: demonstration with basic encephalitogen of the brain (1975) (6)
Immunochemical studies on tyrosinase induction in Neurospora. (1975) (6)
[50] Reaction with N-carboxy-α-amino acid anhydrides. (1972) (6)
Lack of H-2 restriction of suppressor factor specific to myelin basic encephalitogen (1982) (6)
Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymethyl dextran (2004) (6)
Antibodies and Dextran as Anti-Tumour Drug Carriers (1982) (6)
Student Unrest in India (1973) (6)
Flagella as a platform for epitope-based vaccines. (2006) (6)
Immunogenicity and antigenic specificity of the loop fragment of lysozyme (1974) (6)
Ion fluxes changes during early stages of Schistosoma mansoni. Evaluation of complement effect. (1986) (6)
Proteosome delivery of a protective 9B-antigen against Schistosoma mansoni. (1999) (6)
Viroimmunoassay utilizing a synthetic peptide: a test equivalent to the carcinoembryonic antigen radioimmunoassay. (1977) (6)
Cytotoxicity of streptavidin-blocked biotinyl-ricin is retrieved by in vitro immunotargeting via biotinyl monoclonal antibody. (1992) (5)
Titration of myelin oligodendrocyte glycoprotein (MOG) - Induced experimental autoimmune encephalomyelitis (EAE) model (2020) (5)
Anti-viral activity induced by synthetic peptides corresponding to regions involved in viral neutralization☆ (1979) (5)
CHAPTER 14 – Antigenic Determinants of Proteins and Synthetic Vaccines (1984) (5)
Antibodies to cholera toxin synthetic peptides of increasing size and their reactivity with related toxins. (1986) (5)
Acetylcholinesterase from Schistosoma mansoni: interaction of globular species with heparin. (1999) (5)
Lipid-specific antibodies elicited with synthetic lipid conjugates. (1974) (5)
Hexosaminidases A and B from human placenta. (1978) (5)
Proceedings: Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. (1975) (5)
Immunological relationships among hexosaminidases of different species. (1976) (5)
Antibodies to Enzymes (1971) (5)
ECTO- AND EXO-PROTEIN KINASES IN SCHISTOSOMA MANSONI: REGULATION OF SURFACE PHOSPHORYLATION BY ACETYLCHOLINE AND IDENTIFICATION OF THE ALPHA SUBUNIT OF CKII AS A MAJOR SECRETED PROTEIN KINASE (2005) (4)
The therapeutic effect of TV-5010 in a murine model of inflammatory bowel disease -- Dextran induced colitis. (2008) (4)
Activation of influenza-specific memory cytotoxic T lymphocytes by Concanavalin A stimulation. (1998) (4)
Does glatiramer acetate induce neurogenesis in experimental autoimmune encephalomyelitis? (2007) (4)
Identification of Schistosoma mansoni antigens by means of biologically active monoclonal antibodies. (1985) (4)
Synthetic peptides of Shiga toxin B-subunit induce antibodies which neutralize the biological activities of the toxin. (1986) (4)
Copolymer-l Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis (1996) (4)
[69] Reaction with N-carboxy-α-amino acid anhydrides (1967) (4)
Hexosaminidase A in amniotic fluid of Tay-Sachs fetuses. (1978) (4)
Immunomodulation of experimental allergic encephalomyelitis. (1993) (3)
Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis (2021) (3)
Enhanced myelination in autoimmunity and in normal development induced by glatiramer acetate. (2014) (3)
Chemical Characterization and Subunit Structure of Human N-Acetylhexosaminidases A and (3)
Muslim Revivalism and Higher Education (1982) (3)
ANTI-INFLUENZA HEMAGGLUTININ RESPONSE INDUCED WITH SYNTHETIC ANTIGEN (1981) (3)
Synthetic vaccines based on peptides, oligonucleotides and conjugate antigens. (1997) (3)
Conformational Antigenic Determinants in Proteins (1983) (3)
Synthetic Peptide-Based Vaccines Against Influenza (2004) (3)
Synthetic Antigens and Vaccines (1984) (3)
Cystine and other aminoacids in fingernails of cystinuric patients. (1965) (3)
Preclinical efficacy of a virus-like particle-based vaccine against avian influenza H5N1. (2009) (3)
The use of antibodies and polymers as carriers of cytotoxic drugs in the treatment of cancer. (1989) (3)
2-31-01 Copolymer 1 inhibits the response to myelin basic protein p84-102 by T cell receptor antagonism in addition to MHC blocking (1997) (3)
Copolymer 1 induces suppressor T cells of the Th2 type (1996) (2)
Isotype restriction of murine antibodies towards the loop region of hen's egg white lysozyme. (1988) (2)
Thymectomy and chronic relapsing experimental allergic encephalomyelitis in guinea pigs. (1984) (2)
Synthetic vaccines. Volume I. Volume II. (1987) (2)
The Chemistry of Antigenic Determinants on Protein Molecules (1978) (2)
Synthetic peptides as the basis for vaccines against influenza virus and bacterial toxins (1992) (2)
Preparation of antisera to alpha-fetoprotein making use of estradiol affinity column. (1973) (2)
THE COVALENT LINKING OF TWO NUCLEOTIDE ANALOGS TO ANTIBODIES (1985) (2)
Models of autoimmune diseases (1981) (2)
Antibodies to papain. Resolution on DEAE-Sephadex into fractions with different precipitating capacities (1967) (2)
Peptide Interference with APP and Tau Association: Relevance to Alzheimer’s Disease Amelioration (2020) (2)
Antiviral antibodies obtained with aqueous solution of a synthetic antigen. (1980) (2)
Translational Neuroimmunology in Multiple Sclerosis : From Disease Mechanisms to Clinical Applications (2016) (2)
10 – Structural Aspects of Lysozyme – From the Viewpoint of an Antibody (1974) (2)
Author response: Astrocyte morphology is confined by cortical functional boundaries in mammals ranging from mice to human (2016) (2)
Synthetic peptides with antigenic specificity for bacterial toxins. (1986) (2)
Clinical trials of a synthetic polypeptide (Copolymer I) for the treatment of multiple sclerosis (1984) (2)
Site-directed tumor chemotherapy. (1978) (2)
A novel lipid-conjugated marker for the direct labeling of the schistosomulum membrane. (1986) (2)
[Clinical trial of copolymer 1 in multiple sclerosis]. (1989) (2)
Cutting-Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines (2012) (1)
Selective depletion of T regulatory cells reduces but does not eliminate the ability of glatiramer acetate to ameliorate experimental autoimmune encephalomyelitis (P2.192) (2015) (1)
The Consequences of New Approaches in Parasitological Research (1983) (1)
Antiviral effect on MS2 coliphage obtained with a synthetic antigen ( vaccine / viral coat protein / peptide synthesis / peptide-carrier conjugate / phage neutralization ) (1)
vaccines in animal models. sonnei proteosome-lipopolysaccharide intranasal Shigella flexneri 2a and Shigella Immunogenicity and efficacy of oral or (2013) (1)
Synthetic peptide-based vaccines against influenza (1998) (1)
Special issue on Neurobiology and Neuro-Psychiatric Diseases. Editorial. (2009) (1)
Suppression of Demyelinating Diseases by Synthetic Copolymers (1987) (1)
Strategy for approving a universal flu vaccine (2017) (1)
Erratum: Immunoreactivities of polyclonal and monoclonal anti‐T and anti‐Tn antibodies with human carcinoma cells, grown in vivo and in a xenograft model. Int. J. Cancer, 72, 119‐127 (1997) (1997) (1)
Proceedings: Strain differences in the immune response to the encephalytogenic determinant in inbred guinea pigs. (1975) (1)
Cleavage of horse immunoglobulin by cyanogen bromide. (1968) (1)
Differences Amoung Individual CEA Preparations and Carcinomas of Different Origin as Detected by Monoclonal Anti-CEA Antibodies (1984) (1)
Immunospecific drug design--prospects for treatment of autoimmune diseases. (1994) (1)
Immunomodulation of experimental allergic encephalomyelitis by oral administration of Copolymer 1 (Copaxone®) (1998) (1)
Copolymer 1 suppresses chronic-relapsing eae induced in mice by PLP encephalitogenic peptides and interferes with the immune response to these peptides (1995) (1)
Substrate effect of enzyme-antienzyme reaction. (1969) (1)
3-31-25 Suppression of experimental allergic encephalomyelitis by oral administration of copolymer 1 (copaxone®) (1997) (1)
[Preparation and preoperties of poly-DL-alanyl derivatives of a trypsin inhibitor Kunitz and Northrop inhibitor)]. (1968) (0)
COPOLYMER 1 INHIBITS MANIFESTATIONS OF GRAFT REJECTION1 (2001) (0)
Contents, Vol. 108, 1995 (1995) (0)
Astrocyte deformation and neurovascular disruption — Pathological mechanism that mediate neuronal injury and cortical damage in experimental autoimmune encephalomyelitis (2014) (0)
Lack of immunological cross-reaction between bovine alpha-lactalbumin and hen's egg-white lysozyme. (1970) (0)
Proceedings: Immunological cross-reactivity of antibodies to a synthetic undecapeptide of carcino-embryonic antigen with the intact protein and with human sera. (1975) (0)
Proceedings: Purification and characterization of human hexosaminidases. (1975) (0)
Acetylcholinesterase of S. mansoni (Trematode). Interaction of globular species with glycosaminoglycans (1998) (0)
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof (2005) (0)
Immunogenicity andEfficacy ofOral or Intranasal Shigella flexneri 2aandShigella sonnei Proteosome (1993) (0)
Immunity toHeat-Labile Enterotoxins ofPorcine andHuman Escherichia coli Strains Achieved withSynthetic Cholera ToxinPeptides (1986) (0)
Magnetic Resonance Imaging (MRI) Characterization of the Therapeutic Effect of Glatiramer Acetate in Different Models of Experimental Autoimmune Encephalomyelitis (EAE) (P05.109) (2012) (0)
Proceedings: Cellular immunity to myelin basic proteins in experimental allergic neuritis and in related human disorders. (1975) (0)
Verbeserungen in compositions of copolymers containing copolymer-1 (1995) (0)
The Development of Carriers and Adjuvants for use with Peptides to Induce Mucosal and Systemic Immunity against Biologic Toxins (1993) (0)
The copolymer-1 copolymers improvements mixtures (1996) (0)
Mixtures of polypeptides, compositions containing them and processes for obtaining them, and uses thereof (2005) (0)
Enhanced myelination in autoimmunity and in normal development induced by immunomodulatory treatment (2014) (0)
MITIGATING THE IMPACT OF HIV / AIDS ON THE EDUCATION SECTOR IN AFRICA : THE MANAGEMENT CHALLENGE (2002) (0)
Peptides and Polypeptides as Immunomodulators and Their Consequential Therapeutic Effect in Multiple Sclerosis and Other Autoimmune Diseases (2011) (0)
Present situation and prospectives of influenza and cholera toxin vaccine. (1984) (0)
REGULATION OF AUTOIMMUNITY BY THE MODE OF PRESENTATION OF AUTOANTIGEN TO LYMPHOCYTES (1977) (0)
Improvements copolymer-1 copolymer compositions. (1995) (0)
Induction of Th2 suppressor T cells by daily subcutaneous injections of Copolymer 1 (Copaxone®) (1998) (0)
The copolymer-1 copolymer compositions of the improvements (1996) (0)
Specific inhibition by the synthetic copolymer COP-1 of human T cell lines specific to myelin basic protein (1991) (0)
BASIC ENCEPHALITOGEN AND UNRESPONSIVE MULTIPLE SCLEROSIS (1974) (0)
The Christian College (1974) (0)
Pilot trial of Cop 1 in chronic progressive multiple sclerosis: Preliminary report (1989) (0)
Treatment with Oral Laquinimod Augments the In Situ Expression of Brain-Derived Neurotrophic Factor and Reduces CNS Injury (P02.106) (2012) (0)
Antibodies toShiga Holotoxin andtoTwoSynthetic Peptides oftheB Subunit inSeraofPatients with Shigella dysenteriae 1Dysentery (1992) (0)
Anti-influenza Response Induced with Synthetic Antigen (1983) (0)
Synthetic vaccine against viral infections (1982) (0)
Biochemical and Immunochemical Characterization of Hexosaminidase Pt (2001) (0)
Copolymer 1 and Related Peptides as Immunomodulating Agents (2006) (0)
Therapeutic MUC 1-Based Cancer Vaccine Expressed in Flagella — Efficacy in an Aggressive Model of Breast Cancer (2013) (0)
[Basic research in immunology and its impact in the fight against disease]. (1987) (0)
Copolymer 1 for the treatment of inflammatory bowel diseases (2004) (0)
Anti-tumor agent and process for its preparation (1976) (0)
8.14 – Copaxone (2007) (0)
A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy (1980) (0)
Complexes and conjugates of cis-Pt for immunotargeted chemotherapy. (1991) (0)
Neurogeneration and Neuroprotection by Copolymer 1 and Therapeutic Vaccines (2006) (0)
Sa.145. Therapeutic Effect of the Immunomodulators Glatiramer Acetate and Tv5010 on Dextran Sulfate Sodium-Induced Experimental Colitis (2006) (0)
Artificial Antigens and Synthetic Vaccines a Review (1984) (0)
Compositions pharmaceutiques comportant un copolymere peptidique de synthese et servant a la prevention des troubles dus a la reaction greffe contre hote (1996) (0)
Human influenza vaccine, containing four peptides influenza (1999) (0)
S1733 The Beneficial Effect of the Immunomodulator Glatiramer Acetate Treatment on Syndecan-1 Expression in Dextran Sodium Sulfate Colitis (2010) (0)
Subject Index Vol. 108, 1995 (1995) (0)
Chapter 15 – Novel Application for Antibodies (1977) (0)
and Ruth Schistosoma mansoni Protective Peptide-Based Vaccine against Synthesis and Characterization of a (1998) (0)
Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate (2019) (0)
Proceedings: Immunochemical studies of hexosaminidases. (1975) (0)
The antigenicity of man edited by George Kwapinski and Elke H. Kwapinski, Charles C. Thomas, 1981, $24.75 (vii+189 pages) ISBN 1 398 04163 6. (1983) (0)
Specific cytotoxicity of drugs chemically linked to antibody. (1975) (0)
Differences among individual CEA preparations detected by monoclonal antibodies (1982) (0)
Prof. Michael Sela (1924-2022). (2022) (0)
Bystander suppression of experimental autoimmune encephalomyelitis by Th2 suppressor cells specific to copolymer 1 (1997) (0)
Cop 1 for the treatment of inflammatory bowel diseases (2004) (0)
Treatment of multiple sclerosis by ingestion of copolymer-1 (1998) (0)
Development of Synthetic Vaccines (1993) (0)
Ephraim Katchalski-Katzir. 16 May 1916 — 30 May 2009 (2016) (0)
Pharmaceutical compositions containing synthetic peptidcopolymerisate, for the prevention of GVHD (1996) (0)
Improvements in compositions containing copolymers kopolymer-1 (1995) (0)
The reaction of papain with antipapain. (1965) (0)
Can remyelination be enhanced by immunomodulatory therapeutic modality (2018) (0)
Immunological cross-reactivity of antibodies to a synthetic undecapeptide analogous to the amino terminal segment of carcinoembryonic antigen , with the intact protein and with human sera ( synthetic antigen / bacteriophage inactivation / adenocarcinomas ) (0)
Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis (2022) (0)
Vaccine against cholera and against heat-labile e. coli toxin (1984) (0)
Improvements in compositions of copolymers containing copolymer-1 (1995) (0)
Modified responses (1985) (0)
Biological Applications of Synthetic Polypeptides (1991) (0)
Molecules d'acide nucleique, polypeptides, anticorps et compositions les contenant utiles dans le traitement et la detection de l'infection imputable au virus de la grippe (2004) (0)

This paper list is powered by the following services:

Other Resources About Ruth Arnon

en.wikipedia.org

What Schools Are Affiliated With Ruth Arnon?

Ruth Arnon is affiliated with the following schools:

Image Attributions

Image Source for Ruth Arnon